AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
29/09/2026 01:16
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination Sept 29 (Reuters) - HUTCHMED (China) 0013.HK said on Tuesday Anglo-Swedish drugmaker AstraZeneca AZN.L had filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in patients with advanced lung cancer.
ORPATHYS is being jointly developed by AstraZeneca and HUTCHMED and is commercialised by AstraZeneca.
(Reporting by Roshan Thomas in Bengaluru; Editing by Subhranshu Sahu)
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation